Contains Nonbinding Recommendations

Draft Guidance on Encorafenib

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Encorafenib

Dosage Form; Route: Capsule; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 75 mg
   Subjects: Healthy adult males
   Additional comments: Elderly subjects and subjects with history of oral herpes or shingles, or with risk factors for prolonged QTc interval and Torsades de Pointes should be excluded from the study. Subjects should be appropriately monitored for electrocardiogram changes during the study.

---

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 75 mg
   Subjects: Healthy adult males
   Additional comments: See comments above

Analyte to measure (in appropriate biological fluid): Encorafenib in plasma

Bioequivalence based on (90% CI): Encorafenib

Waiver request of in vivo testing: 50 mg based on (i) acceptable bioequivalence studies on the 75 mg strength, (ii) proportional similarity of the formulations across the two strengths, and (iii) acceptable in vitro dissolution testing of the two strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units of the two strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.